Predict your next investment

HEALTHCARE | Biotechnology
ikenaoncology.com

See what CB Insights has to offer

Founded Year

2016

Stage

IPO | IPO

Total Raised

$249M

Date of IPO

3/26/2021

Market Cap

0.14B

Stock Price

13.36

About Ikena Oncology

Ikena Oncology (NASDAQ: IKNA) discovers and develops patient-directed therapies for cancer patients who need life-saving treatment.

Ikena Oncology Headquarter Location

645 Summer Street Suite 101

Boston, Massachusetts, 02210,

United States

857-273-8343

Latest Ikena Oncology News

Ikena Oncology To Participate In Targeted Oncology Panel At The William Blair Biotech Focus Conference 2021

Jul 8, 2021

Ikena Oncology To Participate In Targeted Oncology Panel At The William Blair Biotech Focus Conference 2021 BOSTON, July 08, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company focused on developing therapies targeting key signaling pathways that drive the formation and spread of cancer, today announced that Dr. Author: Jul 8, 2021 7:00 AM EDT BOSTON, July 08, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company focused on developing therapies targeting key signaling pathways that drive the formation and spread of cancer, today announced that Dr. Mark Manfredi, CEO of Ikena Oncology, will participate in a panel discussing next-generation approaches to targeted oncology at the upcoming virtual William Blair Biotech Focus Conference. Details on the panel webcast can be found below. Date: Thursday, July 15, 2021        Time: 9:00 - 9:45 a.m. ET        Webcast Link: Register The panel will be webcast live and can be accessed by visiting the Investors & Media section of the company's website at www.ikenaoncology.com . The webcast will be archived for a period of 30 days following the conclusion of the live event. About Ikena Oncology Ikena Oncology is a targeted oncology company focused on developing cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Ikena is advancing five programs that include four product candidates in either clinical development or IND-enabling studies: IK-930, a TEAD inhibitor targeting the Hippo signaling pathway; an ERK5 inhibitor program targeting the KRAS signaling pathway; IK-175, an AHR antagonist; IK-412, a kynurenine-degrading enzyme; and IK-007, an EP4 receptor antagonist. Ikena has entered into a global strategic collaboration with Bristol-Myers Squibb Company for its IK-175 and IK-412 programs. To learn more visit www.ikenaoncology.com or follow us on Twitter and LinkedIn . Media Contact:Gwen SchankerLifeSci Communications gschanker@lifescicomms.com Investor Contact:Rebecca CohenIkena Oncology rcohen@ikenaoncology.com By

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Ikena Oncology

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Ikena Oncology is included in 4 Expert Collections, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

C

Cancer Therapeutics

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharmaceuticals

7,147 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

C

Cancer

4,844 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

Ikena Oncology Patents

Ikena Oncology has filed 3 patents.

The 3 most popular patent topics include:

  • Transcription factors
  • Clusters of differentiation
  • Immune system
patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/17/2018

6/30/2020

Transcription factors, Immunology, Clusters of differentiation, G protein coupled receptors, Immune system

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

8/17/2018

00/00/0000

00/00/0000

Grant Date

6/30/2020

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Related Topics

Transcription factors, Immunology, Clusters of differentiation, G protein coupled receptors, Immune system

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Ikena Oncology Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Ikena Oncology Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.